Patients' preferences in choosing therapy for retinal vein occlusions

Retina

Volumn 27, Issue 6, 2007, Pages 789-797

  Chang, Margaret A ^a   Fine, Howard F ^a   Bass, Eric ^b   Bressler, Susan B ^a   Schachat, Andrew P ^a   Solomon, Sharon D ^a   Bressler, Neil M ^a,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Retina Division   (United States)

Author keywords

Preference values; Quality of life measurements; Retinal vein occlusion

Indexed keywords

TRIAMCINOLONE;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; FEMALE; HUMAN; LASER COAGULATION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT DECISION MAKING; QUALITY OF LIFE; RATING SCALE; RETINA MACULA EDEMA; STANDARD; UNIVARIATE ANALYSIS; VISUAL ACUITY;

AGED; FEMALE; HUMANS; MACULAR EDEMA, CYSTOID; MALE; PATIENT SATISFACTION; QUALITY OF LIFE; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; SICKNESS IMPACT PROFILE;

EID: 34447304354     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31802c0a34     Document Type: Article

References (53)

1. Hayreh SS. Central retinal vein occlusion. Ophthalmology Clinics of North America 1998;11:559-590.
2. Baseline and early natural history report. The Central Vein Occlusion Study. Arch Ophthalmol 1993;111:1087-1095.
3. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98:271-282.
4. The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995;102:1425-1433.
5. Bashshur ZF, Ma'luf RN, Allam S, et al. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol 2004;122:1137-1140.
6. Chen SD, Lochhead J, Patel CK, Frith P. Intravitreal triamcinolone acetonide for ischaemic macular oedema caused by branch retinal vein occlusion. Br J Ophthalmol 2004;88:154-155.
7. Ip MS, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 2004;122:1131-1136.
8. Ip MS, Kumar KS. Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion. Arch Ophthalmol 2002;120:1217-1219.
9. Jonas JB, Akkoyun I, Kamppeter B, et al. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 2005;19:65-71.
10. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002;240:782-783.
11. Karacorlu M, Ozdemir H, Karacorlu S. Intravitreal triamcinolone acetonide for the treatment of central retinal vein occlusion in young patients. Retina 2004;24:324-327.
12. Krepler K, Ergun E, Sacu S, et al. Intravitreal triamcinolone acetonide in patients with macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 2005;83:71-75.
13. Kwong YY, Lai WW, Lam DS. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 2004;137:593-594; author reply 594.
14. Ozkiris A, Evereklioglu C, Erkilic K, Dogan H. Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion. Eye 2006;20:13-17.
15. Ozkiris A, Evereklioglu C, Erkilic K, Ilhan O. The efficacy of intravitreal triamcinolone acetonide on macular edema in branch retinal vein occlusion. Eur J Ophthalmol 2005;15:96-101.
16. Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 2003;136:419-425.
17. Soto-Pedre E, Hernaez-Ortega MC. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 2004;137:596; author reply 596-597.
18. Williamson TH, O'Donnell A. Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion. Am J Ophthalmol 2005;139:860-866.
19. Opremcak EM, Bruce RA, Lomeo MD, et al. Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases. Retina 2001;21:408-415.
20. Garciia-Arumii J, Boixadera A, Martinez-Castillo V, et al. Chorioretinal anastomosis after radial optic neurotomy for central retinal vein occlusion. Arch Ophthalmol 2003;121:1385-1391.
21. Patelli F, Radice P, Zumbo G, et al. Optical coherence tomography evaluation of macular edema after radial optic neurotomy in patients affected by central retinal vein occlusion. Semin Ophthalmol 2004;19:21-24.
22. Flynn Jr, HW Scott IU. Intravitreal triamcinolone acetonide for macular edema associated with diabetic retinopathy and venous occlusive disease: it's time for clinical trials. Arch Ophthalmol 2005;123:258-259.
23. Bass EB, Marsh MJ, Mangione CM, et al. Patients' perceptions of the value of current vision: assessment of preference values among patients with subfoveal choroidal neovascularization - The Submacular Surgery Trials Vision Preference Value Scale: SST report no. 6. Arch Ophthalmol 2004;122:1856-1867.
24. Bass EB, Wills S, Scott IU, et al. Preference values for visual states in patients planning to undergo cataract surgery. Med Decis Making 1997;17:324-330.
25. Holladay J. Visual acuity measurements. J Cataract Refract Surg 2004;30:287-290.
26. Mangione CM, Lee PP, Pitts J, et al. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). Arch Ophthalmol 1998;116:1496-1504.
27. Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001;119:1050-1058.
28. Deramo VA, Cox TA, Syed AB, et al. Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2003;121:1297-1302.
29. Miskala PH, Hawkins BS, Mangione CM, et al. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization - SST report no. 1. Arch Ophthalmol 2003;121:531-539.
30. Clemons TE, Chew EY, Bressler SB, McBee W. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS report no. 10. Arch Ophthalmol 2003;121:211-217.
31. Dong LM, Childs AL, Mangione CM, et al. Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. Am J Ophthalmol 2004;138:91-108.
32. Miskala PH, Bass EB, Bressler NM, et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST report no. 12. Ophthalmology 2004;111:1981-1992.
33. Miskala PH, Bressler NM, Meinert CL. Relative contributions of reduced vision and general health to NEI-VFQ scores in patients with neovascular age-related macular degeneration. Arch Ophthalmol 2004;122:758-766.
34. Miskala PH, Bressler NM, Meinert CL. Is adjustment of National Eye Institute Visual Function Questionnaire scores for general health necessary in randomized trials? Am J Ophthalmol 2004;137:961-963.
35. Maguire M. Baseline characteristics, the 25-item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). Ophthalmology 2004;111:1307-1316.
36. Lindblad AS, Clemons TE. Responsiveness of the National Eye Institute Visual Function Questionnaire to progression to advanced age-related macular degeneration, vision loss, and lens opacity: AREDS report no. 14. Arch Ophthalmol 2005;123:1207-1214.
37. Morimoto T, Fukui T. Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. J Epidemiol 2002;12:160-178.
38. Brown MM, Brown GC, Sharma S, et al. A utility analysis correlation with visual acuity: methodologies and vision in the better and poorer eyes. Int Ophthalmol 2001;24:123-127.
39. Brown MM, Brown GC, Sharma S, et al. Utility values associated with blindness in an adult population. Br J Ophthalmol 2001;85:327-331.
40. Sharma S, Brown GC, Brown MM, et al. Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients. Br J Ophthalmol 2002;86:493-496.
41. Brown GC, Brown MM, Sharma S, et al. The reproducibility of ophthalmic utility values. Trans Am Ophthalmol Soc 2001;99:199-204.
42. Hollands H, Lam M, Pater J, et al. Reliability of the time trade-off technique of utility assessment in patients with retinal disease. Can J Ophthalmol 2001;36:202-209.
43. Brown MM, Brown GC, Sharma S, et al. Quality of life associated with unilateral and bilateral good vision. Ophthalmology 2001;108:643-647; discussion 647-648.
44. Brown GC, Brown MM, Sharma S, et al. Incremental cost-effectiveness of laser therapy for visual loss secondary to branch retinal vein occlusion. Ophthalmic Epidemiol 2002;9:1-10.
45. Brown MM, Brown GC, Sharma S, Busbee B. Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states. Ophthalmology 2003;110:1076-1081.
46. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol 2000;118:47-51.
47. Post PN, Stiggelbout AM, Wakker PP. The utility of health states after stroke: a systematic review of the literature. Stroke 2001;32:1425-1429.
48. Morse PH. Prospective rationale for and results of argon laser treatment of patients with branch retinal-vein occlusion. Ann Ophthalmol 1985;17:565-571.
49. Finkelstein D. Argon laser photocoagulation for macular edema in branch vein occlusion. Ophthalmology 1986;93:975-977.
50. Age Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-1436.
51. Argon laser photocoagulation for ocular histoplasmosis. Results of a randomized clinical trial. Arch Ophthalmol 1983;101:1347-1357.
52. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Results of a randomized clinical trial. Arch Ophthalmol 1987;105:1499-1507.
53. Brown MM, Brown GC, Sharma S, et al. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol 2002;120:481-484.